Almirall
Almirall is a global pharmaceutical company headquartered in Barcelona, Spain, specializing in dermatology and skin health, with a diverse portfolio of treatments and a strong commitment to research, sustainability, and innovation.
Company Overview
Almirall is a global pharmaceutical company headquartered in Barcelona, Spain. The company focuses on dermatology and skin health, offering treatments for a variety of skin conditions, including psoriasis, actinic keratosis, atopic dermatitis, acne, rare dermatological diseases, onychomycosis, alopecia areata, skin cancer, vitiligo, and hidradenitis suppurativa. Almirall also provides solutions for conditions beyond skin health, such as multiple sclerosis spasticity, chronic pain, diabetes, cardiovascular issues, back pain, allergies, and digestive problems. With a global presence, Almirall operates in over 100 countries and employs more than 1,900 people across 15 subsidiaries.
Research and Development
Almirall invests significantly in research and development (R&D), dedicating 12.4% of its net sales to these efforts. The company has a robust pipeline of new treatments and ongoing clinical trials. Almirall is also involved in numerous partnerships and collaborations to advance its R&D initiatives. One notable program is AlmirallShare, an open innovation platform designed to foster collaboration in dermatology research.
Sustainability and ESG
Almirall has a strong commitment to sustainability, outlined in its Environmental, Social, and Governance (ESG) plan for 2021-2023. The company is a member of the United Nations Global Compact, supporting sustainable development goals. Almirall's sustainability achievements include receiving a Platinum rating from EcoVadis for its ESG performance and certifications under ISO 14001:2015 for environmental management, ISO 50001:2018 for energy management, and ISO 45001:2018 for occupational health and safety management.
Global Presence and Acquisitions
Almirall has a significant global presence, with subsidiaries in Europe and the United States. The company has a history of strategic acquisitions to enhance its product portfolio and market reach. Notable acquisitions include Hermal, Aqua Pharmaceuticals, and Poli Group. Almirall also acquired a portfolio of dermatology products from Allergan in the US, which includes brands like Aczone, Tazorac, Azelex, Cordran Tape, and Seysara.
Dermatology Products and Treatments
Almirall offers a wide range of dermatology products and treatments. These include solutions for common and complex skin conditions such as psoriasis, actinic keratosis, atopic dermatitis, acne, rare dermatological diseases, onychomycosis, alopecia areata, skin cancer, vitiligo, and hidradenitis suppurativa. In Europe, Almirall developed and commercialized aclidinium for COPD (Chronic Obstructive Pulmonary Disease). The company continuously works to expand its dermatology offerings through ongoing research, development, and acquisitions.